KALLELSE TILL EXTRA BOLAGSSTÄMMA I IRLAB THERAPEUTICS AB
IRLAB Therapeutics AB (publ), org.nr 556931-4692, (”IRLAB” eller ”Bolaget”) håller extra bolagsstämma fredagen den 5 juni 2026 kl. 13.00 i Biotech center med adress Arvid Wallgrens Backe 20 i Göteborg. Inpassering och registrering börjar kl. 12.30.
Read More >
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat and reduce risk of falling and falls in Parkinson’s disease.
Kristina Torfgård, CEO, presents at Redeye Healthcare Day 2026
Kristina Torfgård, CEO, presented at Redeye Healthcare Day on April 14, 2026. Presentation in Swedish.
Read More >